GMA 301

Drug Profile

GMA 301

Alternative Names: GMA-301

Latest Information Update: 11 Jan 2017

Price : $50

At a glance

  • Originator Gmax Biopharm
  • Class Antihypertensives; Monoclonal antibodies
  • Mechanism of Action Endothelin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Research Pulmonary arterial hypertension

Most Recent Events

  • 10 Jan 2017 Early research in Pulmonary arterial hypertension in China (Parenteral) before January 2017 (Gmax Biopharm pipeline, January 2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top